Sorrento Therapeutics, Inc. is a clinical stage and commercial biopharmaceutical company focused on delivering innovative and clinically meaningful therapies to address unmet medical needs. Our vision is to leverage our proprietary G-MAB™ library in conjunction with a proprietary targeted delivery modalities to generate the next generation of therapeutics for treating cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. These modalities include proprietary chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy (DAR-T™), antibody-drug conjugates (ADCs), oncolytic virus (Seprehvec™), lymphatic drug targeting (SOFUSA®), as well as bispecific antibody approaches. We are additionally developing pain management solutions, including our clinical candidates resiniferatoxin (RTX) and SEMDEXA™. In response to the global SARS-CoV-2 (“COVID-19”) pandemic, we are also developing and conducting clinical studies for potential coronavirus antiviral therapies and vaccines, including Abivertinib, COVI-MSC™, COVI-AMG™, COVIDROPS™, and COVI SHIELD™, and diagnostic test solutions, such as COVISTIX™ and COVITRACK™.
View Top Employees from Sorrento Therapeutics, Inc.Website | http://www.sorrentotherapeutics.com |
Ticker | SRNE |
Revenue | $57 million |
Funding | $685 million |
Employees | 346 (346 on RocketReach) |
Founded | 2009 |
Address | 4955 Directors Place, San Diego, California 92121, US |
Phone | (858) 203-4100 |
Fax | (858) 203-4028 |
Technologies |
JavaScript,
HTML,
PHP
+56 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Biotechnology, Pharmaceuticals, Science and Engineering, Healthcare, Health Care, Medical |
Web Rank | 1 Million |
Keywords | Biopharmaceuticals, Cancer Therapeutics, Autoimmune Disease, Pain Management |
Competitors | Atara Biotherapeutics, Dynavax Technologies, Kite Pharma, Legend Biotech, Mirati Therapeutics Inc |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 54 Companies, NAICS Code 3254 Companies, NAICS Code 541 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Sorrento Therapeutics, Inc. employee's phone or email?
The Sorrento Therapeutics, Inc. annual revenue was $57 million in 2024.
Mike A is the Chief Medical Officer of Sorrento Therapeutics, Inc..
346 people are employed at Sorrento Therapeutics, Inc..
Sorrento Therapeutics, Inc. is based in San Diego, California.
The NAICS codes for Sorrento Therapeutics, Inc. are [325, 54, 3254, 541, 32, 32541].
The SIC codes for Sorrento Therapeutics, Inc. are [283, 28].